CD38 and Miyoshi myopathy: The sample size of MM with t(11;14) treated with at least two drugs (N = 12) and the new treatments in the relapse setting, such as anti-CD38 monoclonal antibodies, bispecific monoclonal antibodies, and T lymphocytes with chimeric antigen receptors, could have influenced the results.